You’re not selling to one person. |
Forrester’s State of Business Buying found that the average purchase involves 13 people, and 89% of deals span two or more departments. This is why committee mapping matters more than perfect messaging.
Some care about growth, while others care about risk. Some want innovation, and others want stability. And most deals don’t fall apart due to your product’s quality but because of the lack of internal alignment.
In my days as a pharmaceutical territory manager, prescriptions didn’t depend on one physician alone. Pharmacy directors, reimbursement teams, and hospital protocols all shaped the outcome. If I didn’t understand who controlled risk versus who championed value, momentum died quietly. |
B2B buying works the same way: If you’re not mapping the committee, you’re guessing at the decision. |
|
|
Stop over-investing in your champion. |
Champions are typically value owners. They care about performance, speed, and competitive advantage. But every deal includes risk owners. Value owners ask, “Will this help us win?” On the other hand, risk owners ask, “What could go wrong?” |
If your champion can’t answer the second question internally, the deal slows. So, here’s what to do:
🛡 Identify the risk owner early In your first two calls, ask: |
- Who signs off on risk?
-
What would make this decision feel unsafe internally?
- Where have similar initiatives stalled before?
|
These questions uncover friction before it surfaces as “we need more time.”
Buyer journeys rarely match what your CRM suggests. HockeyStack’s self-reported attribution study found that search accounted for 45% of how buyers said they first discovered a company, yet those discovery paths often don’t align with last-touch data.
More importantly, HockeyStack reported that for most prospects, self-reported attribution and last-touch attribution didn’t overlap. That mismatch matters in committee sales. If different stakeholders discover you in different ways — and none of it lines up neatly in your dashboard — then mapping influence inside the buying group becomes even more critical.
📊 Equip for internal defense In my sales experience, I learned quickly that enthusiasm wasn’t enough. Physicians needed clinical data, reimbursement clarity, and safety documentation to move forward. In the same way, your B2B champion needs: |
- ROI models for finance
-
Implementation plans for operations
- Security documentation for IT
- Risk mitigation language for leadership
|
If they can’t defend you internally, they can’t advance you. 🎯 Takeaway: Champions create momentum, while risk owners control velocity. Your job is to align both. |
|
|
Marketing for the whole room |
Most B2B content still assumes a single buyer persona, but buying committees don’t read content the same way. Here’s the difference between the content that value owners and risk owners look for: |
|
|
- Visionary content
- Case studies
- Performance metrics
- Competitive positioning
|
| - Security documentation
- Compliance validation
- Implementation timelines
- Operational impact
|
|
|
Here’s what to do next: 🧠 Build content for the whole room. Most B2B content speaks to the visionary, but few assets address institutional risk. That imbalance creates early excitement and late-stage friction. For every strategic asset, create a risk companion: |
- A CFO summary
- A security brief
- A rollout timeline
- A one-page objection handler
|
Not more content, but better alignment. 📈 Measure buying group coverage. Stop asking only, “How many downloads?” Start asking: |
- Did we reach finance?
- Did IT engage?
- Did procurement receive documentation?
- Was the content forwarded internally?
|
If Issue #1 was about the evolution of measurement, this is about the expansion of influence.
If search drives nearly half (45%) of first discovery moments, according to HockeyStack, then your job isn’t just tracking channels; it’s ensuring both value owners and risk owners encounter proof early enough to influence shortlist formation. 🎯 Final thought: Influence earns shortlist inclusion, but committee alignment closes the deal.
|
|
|
I listened to The Advanced Selling Podcast episode, “The Death of the Decision Maker,” and the message was clear: the old idea of a single “decision maker” is fading. |
|
|
Buying behavior is shifting toward committees, shared risk, and consensus. So, the one-to-one sales playbook (and last-touch attribution) can’t explain why deals move or stall.
The practical lesson I took from it is to stop defending credit and start tracking what actually advances revenue. These include when you entered the shortlist, which stakeholders engaged, and whether the group aligned. Those signals belong in discovery notes and pipeline reviews, not just dashboards.
That also mirrors what I learned managing a pharmaceutical territory. Prescriptions and purchases weren’t won in a single exam room conversation; they cleared a chain of clinical, operational, and risk approvals. The reps who mapped the full “committee” shortened timelines and closed more. Influence earns shortlist inclusion. Consensus creates momentum. And attribution isn’t dead; it just needs context. |
|
|
|
Bianca has spent the past four years helping businesses strengthen relationships and boost performance through strategic sales and customer engagement initiatives. Drawing on her experience in field sales and territory management, she transforms real-world expertise into actionable insights that drive growth and foster lasting client partnerships. |
|
|
Selling Signals is a TechnologyAdvice business © 2026 TechnologyAdvice, LLC. All rights reserved. TechnologyAdvice, 3343 Perimeter Hill Dr., Suite 215, Nashville, TN 37211, USA. |
|
|
|
